Distinct Regulatory and Effector T Cell Metabolic Demands During Graft-Versus-Host Disease

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2019 Dec 4

PMID 31791718

Citations 21

Authors

Keli L Hippen

Ethan G Aguilar

Stephanie Y Rhee

Sara Bolivar-Wagers

Bruce R Blazar

Affiliations

Soon will be listed here.

Abstract

Despite graft-versus-host disease (GVHD) prophylactic agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD. Increasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging inflammatory environment for Treg stability, persistence, and function. Metabolism plays a crucial role in T cell and Treg differentiation, and development of effector function. Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation is a main driver of Treg suppressor function. This review focuses on recent advances in our understanding of Treg metabolism in the context of GVHD, and discusses potential therapeutic applications of Tregs in the prevention or treatment of GVHD in cancer patients.

Citing Articles

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation.

Di Ianni M, Liberatore C, Santoro N, Ranalli P, Guardalupi F, Corradi G Cells. 2024; 13(2).

PMID: 38247827 PMC: 10814899. DOI: 10.3390/cells13020134.

Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.

Li Q, Wang X, Song Q, Yang S, Wu X, Yang D J Clin Invest. 2023; 133(15).

PMID: 37526084 PMC: 10378157. DOI: 10.1172/JCI165723.

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy.

Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D Cancers (Basel). 2023; 15(13).

PMID: 37444586 PMC: 10340266. DOI: 10.3390/cancers15133476.

Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.

Hess N, Kink J, Hematti P Front Immunol. 2023; 14:1143381.

PMID: 37063900 PMC: 10090348. DOI: 10.3389/fimmu.2023.1143381.

New mechanisms of GVHD suppression by Tregs.

Lederer K, Maillard I Blood. 2023; 141(14):1655-1657.

PMID: 37022736 PMC: 10113171. DOI: 10.1182/blood.2022019396.

References

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Choi S, Gatza E, Hou G, Sun Y, Whitfield J, Song Y . Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2014; 125(5):815-9. PMC: 4311228. DOI: 10.1182/blood-2014-10-605238. View

Shono Y, Docampo M, Peled J, Perobelli S, Velardi E, Tsai J . Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016; 8(339):339ra71. PMC: 4991773. DOI: 10.1126/scitranslmed.aaf2311. View

Zeiser R, Nguyen V, Beilhack A, Buess M, Schulz S, Baker J . Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006; 108(1):390-9. PMC: 1895845. DOI: 10.1182/blood-2006-01-0329. View

Liu B, Salgado O, Singh S, Hippen K, Maynard J, Burlingame A . The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. Nat Commun. 2019; 10(1):354. PMC: 6341091. DOI: 10.1038/s41467-019-08300-3. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Jasperson L, Bucher C, Panoskaltsis-Mortari A, Taylor P, Mellor A, Munn D . Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2007; 111(6):3257-65. PMC: 2265461. DOI: 10.1182/blood-2007-06-096081. View

Issa F, Hester J, Goto R, Nadig S, Goodacre T, Wood K . Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation. 2010; 90(12):1321-7. PMC: 3672995. DOI: 10.1097/TP.0b013e3181ff8772. View

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

10.

Armand P, Kim H, Sainvil M, Lange P, Giardino A, Bachanova V . The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016; 173(1):96-104. PMC: 4809783. DOI: 10.1111/bjh.13931. View

11.

McGarry J, Brown N . The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997; 244(1):1-14. DOI: 10.1111/j.1432-1033.1997.00001.x. View

12.

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

13.

Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A . Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15(8):930-9. PMC: 3115752. DOI: 10.1038/nm.2002. View

14.

OConnor R, Guo L, Ghassemi S, Snyder N, Worth A, Weng L . The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018; 8(1):6289. PMC: 5908836. DOI: 10.1038/s41598-018-24676-6. View

15.

Gualdoni G, Mayer K, Goschl L, Boucheron N, Ellmeier W, Zlabinger G . The AMP analog AICAR modulates the Treg/Th17 axis through enhancement of fatty acid oxidation. FASEB J. 2016; 30(11):3800-3809. DOI: 10.1096/fj.201600522R. View

16.

Li H, Sykes M . Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol. 2012; 12(6):403-16. PMC: 4006975. DOI: 10.1038/nri3226. View

17.

Jasperson L, Bucher C, Panoskaltsis-Mortari A, Mellor A, Munn D, Blazar B . Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood. 2009; 114(24):5062-70. PMC: 2788979. DOI: 10.1182/blood-2009-06-227587. View

18.

Thangavelu G, Lee Y, Loschi M, Schaechter K, Feser C, Koehn B . Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. J Immunol. 2019; 202(9):2795-2805. PMC: 6478543. DOI: 10.4049/jimmunol.1800899. View

19.

Gerriets V, Kishton R, Nichols A, Macintyre A, Inoue M, Ilkayeva O . Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest. 2014; 125(1):194-207. PMC: 4382238. DOI: 10.1172/JCI76012. View

20.

MacMillan M, Weisdorf D, Davies S, DeFor T, Burns L, Ramsay N . Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(1):40-6. DOI: 10.1053/bbmt.2002.v8.pm11858189. View